

TISSUE REPAIR ANNOUNCES USA PATENT APPROVAL

Tissue Repair Limited is pleased to announce that its USA patent application 17/390,809 with claims to the method of manufacture of a unique isolated biological polysaccharide, was allowed overnight by the US Patent and Trademark Office (USPTO). This significant achievement is notable as no substantive examination report was issued during prosecution of the patent application.

The application proceeded to allowance with only a recognition and separation of the method of manufacture claims from the other inventions identified to the composition and methods of use of the composition.

The composition and methods of use will be the subject of further related USA patent applications and the potential for additional areas of IP protection around the Company's technology

The allowed patent application represents a core component of the Company's IP and protects the Company's process for the manufacture of its API. There are no known alternative processes from which to produce the Company's proprietary polysaccharide molecule.

Obtaining USA patent application allowance was a core milestone listed in the Company's prospectus which it is pleased to have achieved so rapidly (less than 12 months from filing).

The Company will progress related filings now in the USA and elsewhere in the world to the composition and methods of use. The promising result so far provides considerable confidence in the allowability of further filings.

The Board also wishes to advise that the Company continues to make progress towards the end of Phase II and commencement of its phase III trial program consistent with the Company's Prospectus and prior disclosures.

For further information in relation to this release please contact Darryl Reed at darryl.reed@trtherapeutics.com 0419 557 663.

This announcement has been approved for release by TRP's board.